Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year High - Should You Buy?

Key Points

• Aurinia Pharmaceuticals shares reached a new 52-week high at $12.90, following strong trading volume and a previous close of $12.30.
• Wall Street analysts have a consensus rating of "Buy" for Aurinia, with price targets ranging from $9.00 to $17.00, indicating potential growth.
• Recent insider transactions include Director Kevin Tang acquiring 1,000,000 shares, increasing his total ownership substantially and reflecting confidence in the company's future.

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP hit a new 52-week high during trading on Thursday . The company traded as high as $12.90 and last traded at $12.89, with a volume of 1330837 shares traded. The stock had previously closed at $12.30.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on AUPH shares. HC Wainwright reiterated a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada boosted their price objective on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $13.00.

Aurinia Pharmaceuticals Stock Up 4.8%

The business has a 50-day simple moving average of $11.04 and a two-hundred day simple moving average of $9.07. The stock has a market capitalization of $1.70 billion, a P/E ratio of 29.98 and a beta of 1.26. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The company had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 1,000,000 shares of Aurinia Pharmaceuticals stock in a transaction on Friday, August 1st. The shares were bought at an average price of $10.12 per share, with a total value of $10,120,000.00. Following the completion of the purchase, the director owned 11,029,500 shares in the company, valued at $111,618,540. This trade represents a 9.97% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders acquired a total of 1,300,000 shares of company stock valued at $13,590,000 over the last quarter. 12.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AUPH. Nuveen LLC acquired a new position in Aurinia Pharmaceuticals in the first quarter valued at about $10,014,000. Jupiter Asset Management Ltd. acquired a new position in Aurinia Pharmaceuticals in the first quarter valued at about $6,052,000. Qube Research & Technologies Ltd increased its holdings in shares of Aurinia Pharmaceuticals by 45.1% in the second quarter. Qube Research & Technologies Ltd now owns 1,242,512 shares of the biotechnology company's stock worth $10,524,000 after acquiring an additional 386,364 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Aurinia Pharmaceuticals by 69.7% in the fourth quarter. Woodline Partners LP now owns 849,477 shares of the biotechnology company's stock worth $7,628,000 after acquiring an additional 348,983 shares in the last quarter. Finally, Jump Financial LLC increased its holdings in shares of Aurinia Pharmaceuticals by 669.1% in the second quarter. Jump Financial LLC now owns 390,101 shares of the biotechnology company's stock worth $3,304,000 after acquiring an additional 339,377 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company's stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.